Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BenevolentAI is pioneering AI-driven drug discovery methods

By Brian Buntz | May 3, 2023

Benevolent AI“Can we treat chronic inflammation in ulcerative colitis by reversing immune cell activation in colonic mucosa?” That’s an example of a biological question that the AI-enabled drug discovery firm BenevolentAI (AMS:BAI) would ask when exploring a new drug target.

Incorporating a disease, sign, mechanism and tissue into a single question provides focal points for the company’s AI models to explore when generating target hypotheses, said Anne Phelan, chief scientific officer of Benevolent AI in a presentation at the Royal Society earlier this year.

BenevolentAI’s strategy involves a comprehensive understanding of the biological systems underlying various diseases, breaking down silos in clinical areas and tapping diverse multimodal data to discover novel therapeutic targets. For ulcerative colitis, the company’s AI models sift through vast amounts of scientific literature and data to spot promising targets and pathways that could potentially alleviate the chronic inflammation in the colonic mucosa associated with the condition.

Extracting insights

The approach offers hope in extracting actionable items from the overwhelming sea of data scientists continue to generate. “We are drowning in a sea of data and starving for knowledge,” Phelan said.

The growing amount of data, matched with ever-more powerful AI tools, makes it possible to ask unprecedented questions. “Now more than ever, we have the capacity to really ask drastically more complex questions and queries of the data at our disposal with real-time information,” Phelan added.

BenevolentAI’s focus is using AI to identify dysregulated biological systems and pathways that could be targeted for therapeutic intervention. “Our approach at Benevolent is to use AI and machine learning to interrogate the vast amounts of genomic, transcriptomic and proteomic data,” Phelan explained.

Phelan emphasized the importance of integrating different types of data to uncover new insights. For instance, she mentioned, “Our suite of algorithms enables us to predict targets based on this foundational data and knowledge graph.”

An iterative approach

Additionally, BenevolentAI’s platform allows for iterative learning, meaning that as new data and knowledge emerge, the AI models can refine their predictions and hypotheses, ultimately leading to more accurate and effective drug target identification. Phelan stated, “This allows the [intentions] of the scientists to be recorded within the platform, but it also creates a virtuous cycle of learning and decision making within or on the platform.”

In addition to the work on ulcerative colitis, Phelan shared several other examples of the AI-driven research at BenevolentAI, highlighting the versatility and potential of their platform to address complex and challenging diseases. She noted, “We’re looking at a disease agnostic format, we’re looking at modality agnostic assessments of targets, and it’s repeatable.”


Filed Under: Data science, Drug Discovery and Development, machine learning and AI
Tagged With: AI drug discovery, AI in healthcare, BenevolentAI, biotechnology, drug development, healthcare innovation, novel therapeutic targets
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Abstract neural network
Inside IQVIA’s quest to build a multi-agent AI ‘dream team’ to transform clinical trials
Xaira and Verily co-founder ponders low-hanging fruit and blue-sky potential in FDA’s genAI rollout
Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE